Buprenorphine Treatment For Opioid Use Disorder: Comparison Of Insurance Restrictions, 2017–21-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Buprenorphine Treatment For Opioid Use Disorder: Comparison Of Insurance Restrictions, 2017–21

Published:2023-05-01 Issue:5 Volume:42 Page:658-664
ISSN:0278-2715
Container-title:Health Affairs
language:en
Short-container-title:Health Affairs

Author:

Andraka-Christou Barbara¹,Simon Kosali I.²,Bradford W. David³,Nguyen Thuy⁴

Affiliation:

1. Barbara Andraka-Christou (), University of Central Florida, Orlando, Florida.

2. Kosali I. Simon, Indiana University, Bloomington, Indiana.

3. W. David Bradford, University of Georgia, Athens, Georgia.

4. Thuy Nguyen, University of Michigan, Ann Arbor, Michigan.

Publisher

Health Affairs (Project Hope)

Subject

Health Policy

Reference45 articles.

1. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality

2. Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence

3. Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019”

4. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder

5. Characteristics and current clinical practices of opioid treatment programs in the United States

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018–2022;Addiction;2024-08-16

2. Treatment setting and buprenorphine discontinuation: an analysis of multi-state insurance claims;Addiction Science & Clinical Practice;2024-03-16

3. US payment policy for medications to treat opioid use disorder: landscape and opportunities;Health Affairs Scholar;2024-02-27

4. Availability of Long-Acting Injectable Buprenorphine at Substance Use Treatment Facilities in 2021;JAMA;2024-02-13

5. Use of in-network insurance benefits is critical for improving retention in telehealth-based buprenorphine treatment;Health Affairs Scholar;2024-01-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3